Milk Components and Metabolic Syndrome

The Effect of Milk, Whey and Casein on Weight Loss and Risk Markers of Metabolic Syndrome in Overweight Children

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00785499

Acronym

MoMS

Enrollment

193

Registered

2008-11-05

Start date

2008-11-30

Completion date

2011-07-31

Last updated

2012-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome, Obesity

Keywords

obesity, metabolic syndrome, milk components, casein, whey, children, adolescent

Brief summary

Milk contains a vast number of bioactive components that have been suggested to have a positive impact on human health, of special interest is the effects related to metabolic syndrome and obesity but the effect of the individual milk components is not clear. This study examine whether it is beneficial for overweight and obese children to increase the intake of skim milk, or whey or casein in relation to bodyweight and markers of MS. The participants will be randomized to receive skim milk, whey milk drink, casein milk drink or mineral water for 3 mo. They will be examined at baseline, end of intervention and followed up 3 month later.

Interventions

BEHAVIORALMilk Components and Metabolic syndrome

1 liter per day of the test drinks for 3 mo

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

PREVENTION

Masking

TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

12 Years to 15 Years

Healthy volunteers

Yes

Inclusion criteria

* 12 years to 15 years old * iso BMI larger than 25 * habitual milk intake less than 250 ml/day * non-smoker * healthy at the time of inclusion

Exclusion criteria

* chronic illnesses * intake of antibiotic 1 mo before start of intervention

Design outcomes

Primary

Measure	Time frame
body composition and markers for metabolic syndrome (e.g.fasting insulin, glucose, lipid profile, CRP, PAI-1, tPA)	at baseline, after intervention and body composition 3 mo after end of intervention

Secondary

Measure	Time frame
diet	baseline and end of intervention
pulse wave velocity,	baseline and end of intervention
blood pressure, metabolomics, IFG-I, IGFBP-3, appetite regulatory hormones,immune parameters, bone turn over parameters, composition of microbiota, vitamin D, physical activity	baseline and end of intervention

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026